Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
deals
7
×
life sciences
national blog main
san francisco blog main
san francisco top stories
biotech
national top stories
fda
investing
new york blog main
new york top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
cancer immunotherapy
cstone pharmaceuticals
curevac
eli lilly
nonalcoholic steatohepatitis
roche
sanofi
What
cancer
7
×
bio
roundup
drug
medicines
promise
vaccine
amid
bombast
cash
caught
coronavirus
debate
develop
discussion
efforts
hasn’t
meso’s
miss
pandemic
pfizer’s
pharmaceutical
presidential
response
tuesday’s
viewers
ahead
ambien
american
annual
appetite
approval
asco
attendees
attention
bets
biotech
black
blueprint
bread
Language
unset
Current search:
deals
×
cancer
×
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More